Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Arcus Biosciences ( (RCUS) ).
On February 6, 2025, Merdad Parsey, M.D., Ph.D., resigned from Arcus Biosciences’ Board of Directors following his departure from Gilead Sciences, Inc. The Board appointed Dietmar Berger, M.D., Ph.D., as a Class II director to replace Dr. Parsey. Dr. Berger, who joined Gilead as Chief Medical Officer in January 2025, will not receive compensation for his role at Arcus. This change aligns with the Amended and Restated Investor Rights Agreement between Arcus and Gilead.
More about Arcus Biosciences
Arcus Biosciences operates in the biopharmaceutical industry, focusing on developing innovative cancer therapies. The company is committed to advancing its pipeline of immuno-oncology treatments, aiming to address unmet medical needs in oncology.
YTD Price Performance: -10.31%
Average Trading Volume: 704,985
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.24B
Learn more about RCUS stock on TipRanks’ Stock Analysis page.
